Loading...
•
Sep 30, 2024
iBio Q1 2025 Earnings Report
iBio reported financial results for the fiscal first quarter ended September 30, 2024.
Key Takeaways
iBio reported no revenue for the first quarter ended September 30, 2024. The net loss from continuing operations was approximately $4.0 million, or $0.46 per share. Cash, cash equivalents and restricted cash totaled approximately $11.3 million.
Advanced myostatin program with dosing underway in non-human primate study.
Collaboration with AstralBio progressed, manufacturing and dosing a lead molecule.
Kristi Sarno was appointed as Senior Vice President of Business Development.
R&D and G&A expenses decreased by approximately 20% due to cash preservation strategy.